Sung Ji Nam
Stock Analyst at Scotiabank
(1.94)
# 2,970
Out of 4,840 analysts
78
Total ratings
38.46%
Success rate
-9.12%
Average return
Main Sectors:
Stocks Rated by Sung Ji Nam
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CSTL Castle Biosciences | Maintains: Sector Outperform | $44 → $40 | $15.96 | +150.63% | 6 | May 21, 2025 | |
| BDSX Biodesix | Maintains: Sector Outperform | $3 → $2 | $0.36 | +449.45% | 2 | May 21, 2025 | |
| MYGN Myriad Genetics | Downgrades: Sector Perform | $20 → $6 | $3.90 | +53.85% | 4 | May 21, 2025 | |
| GH Guardant Health | Maintains: Sector Outperform | $52 → $57 | $37.92 | +50.32% | 5 | May 5, 2025 | |
| TMO Thermo Fisher Scientific | Maintains: Sector Perform | $650 → $605 | $391.37 | +54.59% | 14 | Apr 25, 2025 | |
| BNGO Bionano Genomics | Maintains: Sector Perform | $1 → $4 | $3.73 | +7.24% | 6 | Apr 2, 2025 | |
| PACB Pacific Biosciences of California | Maintains: Sector Outperform | $6 → $2 | $0.95 | +111.64% | 5 | Mar 25, 2025 | |
| EXAS Exact Sciences | Maintains: Sector Outperform | $70 → $73 | $56.67 | +28.83% | 2 | Feb 24, 2025 | |
| ADPT Adaptive Biotechnologies | Maintains: Sector Outperform | $10 → $12 | $8.81 | +36.21% | 2 | Feb 13, 2025 | |
| WAT Waters | Upgrades: Sector Outperform | $430 → $450 | $342.11 | +31.54% | 2 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $88 → $90 | $46.55 | +93.34% | 2 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $54 → $62 | $27.80 | +123.02% | 5 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Perform | $265 | $183.58 | +44.35% | 1 | Dec 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $40 → $44 | $27.02 | +62.84% | 4 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $35 | $16.98 | +106.12% | 4 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $176 → $164 | $79.33 | +106.73% | 9 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $6 | $5.99 | +0.17% | 2 | Jun 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $20.24 | - | 3 | Nov 24, 2020 |
Castle Biosciences
May 21, 2025
Maintains: Sector Outperform
Price Target: $44 → $40
Current: $15.96
Upside: +150.63%
Biodesix
May 21, 2025
Maintains: Sector Outperform
Price Target: $3 → $2
Current: $0.36
Upside: +449.45%
Myriad Genetics
May 21, 2025
Downgrades: Sector Perform
Price Target: $20 → $6
Current: $3.90
Upside: +53.85%
Guardant Health
May 5, 2025
Maintains: Sector Outperform
Price Target: $52 → $57
Current: $37.92
Upside: +50.32%
Thermo Fisher Scientific
Apr 25, 2025
Maintains: Sector Perform
Price Target: $650 → $605
Current: $391.37
Upside: +54.59%
Bionano Genomics
Apr 2, 2025
Maintains: Sector Perform
Price Target: $1 → $4
Current: $3.73
Upside: +7.24%
Pacific Biosciences of California
Mar 25, 2025
Maintains: Sector Outperform
Price Target: $6 → $2
Current: $0.95
Upside: +111.64%
Exact Sciences
Feb 24, 2025
Maintains: Sector Outperform
Price Target: $70 → $73
Current: $56.67
Upside: +28.83%
Adaptive Biotechnologies
Feb 13, 2025
Maintains: Sector Outperform
Price Target: $10 → $12
Current: $8.81
Upside: +36.21%
Waters
Feb 13, 2025
Upgrades: Sector Outperform
Price Target: $430 → $450
Current: $342.11
Upside: +31.54%
Feb 6, 2025
Maintains: Sector Outperform
Price Target: $88 → $90
Current: $46.55
Upside: +93.34%
Feb 4, 2025
Maintains: Sector Outperform
Price Target: $54 → $62
Current: $27.80
Upside: +123.02%
Dec 23, 2024
Initiates: Sector Perform
Price Target: $265
Current: $183.58
Upside: +44.35%
Nov 8, 2024
Maintains: Sector Outperform
Price Target: $40 → $44
Current: $27.02
Upside: +62.84%
Nov 5, 2024
Maintains: Buy
Price Target: $40 → $35
Current: $16.98
Upside: +106.12%
Aug 15, 2024
Maintains: Sector Outperform
Price Target: $176 → $164
Current: $79.33
Upside: +106.73%
Jun 29, 2023
Assumes: Buy
Price Target: $6
Current: $5.99
Upside: +0.17%
Nov 24, 2020
Downgrades: Neutral
Price Target: n/a
Current: $20.24
Upside: -